FibroGen, Inc.

FGEN

After the markets closed on April 6, 2021, FibroGen admitted that prior disclosures regarding its safety analyses from the roxadustat Phase 3 program included post-hoc changes to the stratification factors. FibroGen said it would conduct a “comprehensive internal review to ensure” that such errors do not occur again. On this news, FibroGen’s shares fell $14.90 per share, or approximately 43%, to close at just $19.74 per share on April 7, 2021.

Lead Plaintiff deadline
June 11, 2021
class period
November 8, 2019
to
April 6, 2021
Case Documents
No documents available. Contact us if you need a case document.